Thomas DiRaimondo - Jan 2, 2025 Form 4 Insider Report for Janux Therapeutics, Inc. (JANX)

Role
Chief Scientific Officer
Signature
/s/ James Pennington, Attorney-in-Fact
Stock symbol
JANX
Transactions as of
Jan 2, 2025
Transactions value $
$0
Form type
4
Date filed
1/3/2025, 08:10 PM
Previous filing
Sep 27, 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction JANX Common Stock Award $0 +24K +22.7% $0.00 130K Jan 2, 2025 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction JANX Stock option (right to buy) Award $0 +84K $0.00 84K Jan 2, 2025 Common Stock 84K $53.24 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents the grant of restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs vest in four equal annual installments beginning on January 1, 2026.
F2 Includes 497 shares acquired under the Issuer's 2021 Employee Stock Purchase Plan (the "Plan") on November 15, 2021, 1,327 shares acquired under the Plan on May 13, 2022, 1,130 shares acquired under the Plan on November 15, 2022, 1,715 shares acquired under the Plan on May 15, 2023, 763 share acquired under the Plan on November 15, 2023, 1,406 shares acquired under the Plan on May 15, 2024 and 943 shares acquired under the Plan on November 15, 2024.
F3 25% of the shares subject to the option vest on January 1, 2026 and the balance will vest in equal monthly installments thereafter over a three year period.